ABP

Abpro Holdings, Inc. operates as a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology and immunology applications. Headquartered in Woburn, Massachusetts, the company specializes in discovering and engineering novel therapeutic antibodies using its proprietary technology platforms. Abpro's core business model centers on advancing its pipeline of antibody drug candidates through preclinical and clinical development, while also engaging in strategic partnerships and licensing agreements with larger pharmaceutical companies. The company's lead programs target immuno-oncology pathways and include multiple antibodies designed to modulate immune checkpoint proteins and other cancer-related mechanisms. Abpro leverages its DiversImmune and Multimmune technology platforms to generate diverse antibody libraries and identify therapeutic candidates with enhanced properties. As a development-stage enterprise, the company has not yet generated significant product revenue and relies primarily on research funding, partnerships, and capital raises to finance operations. In recent years, Abpro has focused on advancing select candidates through early-stage clinical trials while seeking collaboration opportunities to maximize the value of its antibody discovery platforms. The company maintains research facilities in Massachusetts and employs a lean team of scientists and drug development professionals focused on translating its antibody engineering capabilities into potential treatments for cancer and immune-mediated diseases.